An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People with Advanced HIV: A Prospective International Cohort Study.
HIV
biomarkers
immune reconstitution inflammatory syndrome (IRIS)
tuberculosis
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
received:
02
06
2020
accepted:
07
08
2020
pubmed:
8
8
2020
medline:
11
2
2022
entrez:
8
8
2020
Statut:
ppublish
Résumé
Immune reconstitution inflammatory syndrome (IRIS) is a common cause of morbidity among people with human immunodeficiency virus (PWH) who initiate antiretroviral therapy (ART) with severe lymphopenia. Easily accessible tools that reliably predict emergence and elucidate pathogenesis of IRIS are needed to facilitate improved clinical management. Plasma levels of biomarkers were measured before ART initiation in a large multinational cohort of ART-naive PWH with severe immunosuppression (CD4+ count <100 cells/mm3) in United States, Kenya, and Thailand. We performed a series of multiparametric analyses of inflammatory and clinical biomarkers and developed a composite score merging relevant biomarkers for use in a prediction model. We identified a distinct baseline inflammatory profile and changes in inflammatory networks among biomarkers in participants who subsequently developed mycobacterial or viral IRIS. We also developed a composite score incorporating biomarkers associated with IRIS (interleukin-6 [IL-6], IL-10, IL-27, sCD14, interferon-γ, tumor necrosis factor-α, hyaluronic acid, D-dimer, body mass index, and hemoglobin) that accurately predicted mycobacterial IRIS and death in this cohort. Systemic inflammatory profiles in PWH with severe immunosuppression are predictive of IRIS. Composite scores for the prediction of mycobacterial IRIS and death could be useful for risk stratification in PWH and lymphopenia initiating ART. NCT00286767.
Sections du résumé
BACKGROUND
Immune reconstitution inflammatory syndrome (IRIS) is a common cause of morbidity among people with human immunodeficiency virus (PWH) who initiate antiretroviral therapy (ART) with severe lymphopenia. Easily accessible tools that reliably predict emergence and elucidate pathogenesis of IRIS are needed to facilitate improved clinical management.
METHODS
Plasma levels of biomarkers were measured before ART initiation in a large multinational cohort of ART-naive PWH with severe immunosuppression (CD4+ count <100 cells/mm3) in United States, Kenya, and Thailand. We performed a series of multiparametric analyses of inflammatory and clinical biomarkers and developed a composite score merging relevant biomarkers for use in a prediction model.
RESULTS
We identified a distinct baseline inflammatory profile and changes in inflammatory networks among biomarkers in participants who subsequently developed mycobacterial or viral IRIS. We also developed a composite score incorporating biomarkers associated with IRIS (interleukin-6 [IL-6], IL-10, IL-27, sCD14, interferon-γ, tumor necrosis factor-α, hyaluronic acid, D-dimer, body mass index, and hemoglobin) that accurately predicted mycobacterial IRIS and death in this cohort.
CONCLUSIONS
Systemic inflammatory profiles in PWH with severe immunosuppression are predictive of IRIS. Composite scores for the prediction of mycobacterial IRIS and death could be useful for risk stratification in PWH and lymphopenia initiating ART.
CLINICAL TRIALS REGISTRATION
NCT00286767.
Identifiants
pubmed: 32761193
pii: 5881925
doi: 10.1093/infdis/jiaa484
pmc: PMC8030712
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT00286767']
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1275-1283Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI115940
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Nat Rev Microbiol. 2012 Jan 09;10(2):150-6
pubmed: 22230950
AIDS. 2013 Jun 19;27(10):1603-13
pubmed: 23462220
Am J Respir Crit Care Med. 2012 Aug 15;186(4):369-77
pubmed: 22700860
Clin Infect Dis. 2020 Nov 5;71(8):1905-1911
pubmed: 31665254
Nat Commun. 2015 Sep 24;6:8451
pubmed: 26399326
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):309-18
pubmed: 21826013
Curr Opin HIV AIDS. 2016 Mar;11(2):191-200
pubmed: 26720550
PLoS One. 2013 Nov 28;8(11):e81856
pubmed: 24312369
Lancet Infect Dis. 2005 Jun;5(6):361-73
pubmed: 15919622
J Exp Med. 2015 Aug 24;212(9):1449-63
pubmed: 26282876
PLoS One. 2013 May 17;8(5):e63541
pubmed: 23691062
Mediators Inflamm. 2016;2016:2856213
pubmed: 27597803
EMBO Mol Med. 2013 May;5(5):661-74
pubmed: 23592557
Sci Rep. 2019 May 29;9(1):8002
pubmed: 31142816
EBioMedicine. 2016 Jan 14;4:115-23
pubmed: 26981576
PLoS One. 2019 Oct 10;14(10):e0223267
pubmed: 31600337
PLoS One. 2011;6(7):e22401
pubmed: 21789257
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28084192
PLoS Negl Trop Dis. 2019 Jun 24;13(6):e0007535
pubmed: 31233500
J Infect Dis. 2004 Sep 1;190(5):869-78
pubmed: 15295690
PLoS One. 2016 Nov 21;11(11):e0166954
pubmed: 27870882
Cytokine. 2019 Nov;123:154759
pubmed: 31226436
Curr Opin HIV AIDS. 2010 Nov;5(6):504-10
pubmed: 20966640
J Infect Dis. 2020 Jul 23;222(4):670-680
pubmed: 32311029
J Infect Dis. 2013 May 1;207(9):1379-88
pubmed: 23335804
J Acquir Immune Defic Syndr. 2010 Apr;53(5):589-97
pubmed: 19801945
Clin Infect Dis. 2020 Jul 27;71(3):652-660
pubmed: 31504347
AIDS. 2010 Sep 24;24(15):2381-90
pubmed: 20808204
BMC Infect Dis. 2016 Aug 05;16:368
pubmed: 27494953
PLoS Pathog. 2014 Oct 02;10(10):e1004433
pubmed: 25275318
Expert Rev Clin Immunol. 2014 May;10(5):631-45
pubmed: 24580108